Skip to content

Application and Effect Evaluation of Medium Chain Fatty Acid Rich Milk Powder in Infants With Cholestatic Liver Disease

Application and Effect Evaluation of Medium Chain Fatty Acid Rich Milk Powder in Infants With Cholestatic Liver Disease

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05922332
Enrollment
0
Registered
2023-06-28
Start date
2025-04-01
Completion date
2025-12-30
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholestatic Liver Disease

Brief summary

To verify the effect of feeding milk powder rich in medium chain fatty acids on improving the nutritional status and disease status of infants with cholestatic liver disease and To evaluate the safety of feeding milk powder rich in medium chain fatty acids in infants with cholestatic liver disease.

Detailed description

This study will include all types of cholestatic liver disease in infants, randomized controlled study of the efficacy and safety of intervention with rich medium chain fatty acid milk powder,To verify the effect of feeding milk powder rich in medium chain fatty acids on improving the nutritional status and disease status of infants with cholestatic liver disease .

Interventions

DIETARY_SUPPLEMENTRich medium chain fatty acid milk powder group

In intervention group,there are 32 infants.They will be fed with rich medium chain fatty acid milk powder, formula with MCT content of 39%, total energy of 68kcal/100ml, and feeding frequency at a 3-hour interval

DIETARY_SUPPLEMENTRegular milk powder group

In control group,there are 32 infants.They will be fed regular milk powder,formula with MCT content of less than 30%, total energy of 67kcal/100ml, and feeding frequency at a 3 hours interval

Sponsors

Children's Hospital of Fudan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Months to 6 Months
Healthy volunteers
Yes

Inclusion criteria

* meets the diagnostic criteria of cholestasis * Artificial feeding (formula feeders) * Age ≤6 months * The course of cholestasis was \> 1 month * Informed consent of the guardian

Exclusion criteria

* There are major non-cholestatic genetic diseases leading to nutritional intake disorders, such as gastrointestinal malformations * Cholestasis with ascites and diarrhea * In patients with oxidative impairment of medium chain fatty acids

Design outcomes

Primary

MeasureTime frameDescription
Z-scores of weight for agefrom enrollment to the 4 weekend(28 days)The change of WAZ would be calculation at the 4 weekend(28 days) after enrollment.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026